Press Release

Publication of insider information pursuant to Art. 17 MAR

Change of President and CEO at Carl Zeiss Meditec AG

7 May 2025

Jena, Germany | May 7, 2025 | Carl Zeiss Meditec AG

The supervisory board of Carl Zeiss Meditec AG (ISIN: DE0005313704) in today’s meeting has agreed on a change in the Management Board of the company. Dr. Markus Weber, President and CEO of Carl Zeiss Meditec AG since January 1, 2022, will turn over his position to Maximilian Foerst, currently Head of ZEISS Greater China, on May 31, 2025. The handover is taking place at Dr. Weber’s own request and on best of terms with the Supervisory Board.

Maximilian Foerst joined Carl Zeiss AG in 1995 and, following initial roles in product management and marketing in the medical technology field, took over leadership of the Carl Zeiss sales and service companies in France and Korea and – since 2009 - ZEISS Greater China. Under his leadership, ZEISS achieved market leadership in the Refractive Laser business as well as a leading position in the intraocular lense business in China.
The region Greater China is the largest single market for Carl Zeiss Meditec AG with a revenue share of 26% in fiscal year 2023/24.

Along with his new role as President and CEO of Carl Zeiss Meditec AG, Maximilian Foerst has also been nominated as an Executive Board member of Carl Zeiss AG and will take over Dr. Weber’s responsibilities. Dr. Weber will leave the Executive Board of Carl Zeiss AG likewise on May 31, 2025.

In the view of the Supervisory Board of Carl Zeiss Meditec AG, management continuity is assured via the internal succession. The Chief Financial Officer, Justus Felix Wehmer remains in office. Leadership of the Strategic Business Units Ophthalmology and Microsurgery remains unchanged as well.

Press & Investor Relations Contact Sebastian Frericks

Head of Group Finance & Investor Relations
Carl Zeiss Meditec AG
Phone: +49 3641 220 116
investors.med@zeiss.com

Brief profile

Carl Zeiss Meditec AG (ISIN: DE0005313704), which is listed on the MDAX and TecDAX of the German stock exchange, is one of the world's leading medical technology companies. The Company supplies innovative technologies and application-oriented solutions designed to help doctors improve the quality of life of their patients. The Company offers complete solutions, including implants and consumables, to diagnose and treat eye diseases. The Company creates innovative visualization solutions in the field of microsurgery. With 5,730 employees worldwide, the Group generated revenue of €2,066.1m in fiscal year 2023/24 (to 30 September).

The Group’s head office is located in Jena, Germany, and it has subsidiaries in Germany and abroad; more than 50 percent of its employees are based in the USA, Japan, Spain and France. The Center for Application and Research (CARIn) in Bangalore, India and the Carl Zeiss Innovations Center for Research and Development in Shanghai, China, strengthen the Company's presence in these rapidly developing economies. Around 39 percent of Carl Zeiss Meditec AG’s shares are in free float. Approx. 59 percent are held by Carl Zeiss AG, one of the world’s leading groups in the optical and optoelectronic industries.

For more information visit our website at www.zeiss.com/med


Share this page